MAPT and Alzheimer disease: The superior performance of tau‐PET may be particularly advantageous in symptomatic stages, where higher baseline tau predicts faster decline and helps distinguish variant AD subtypes characterized by distinct spatial patterns of accumulation.13, 38, 41